A scene-by-scene explanation of satiety signaling, slower gastric emptying, insulin response, and why patients describe the sudden quieting of food noise.
Open interactiveGLP-1 coverage is tightening in 2026, not disappearing. Learn why costs are driving stricter prior authorization and diabetes-vs-weight-loss distinctions, and what questions to ask your doctor, HR team, or insurer to protect your access.
Read moreGive someone arriving cold a grounded, jargon-free answer to what GLP-1 medications are, who they are for, and what they actually do in the body.
Read moreA plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreAcross GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 coverage is tightening in 2026, not disappearing. Learn why costs are driving stricter prior authorization and diabetes-vs-weight-loss distinctions, and what questions to ask your doctor, HR team, or insurer to protect your access.
Full analysisWe track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Started publishing Jan 2021
Howard Luks is worth reading if you care about what happens after the first burst of weight loss. His work is especially good on exercise, muscle, mobility, and the physical tradeoffs that can get lost in more medication-centered coverage. This is a strong companion read for people trying to connect weight loss with long-term function and strength.
Started publishing Jan 2025
GLP-1 Chronicles is useful because it sounds like a person, not a health system. The writing captures lived experience, setbacks, milestones, and the emotional texture around treatment in a way more formal publications usually do not. Read it when you want the patient-side view of this category, not institutional analysis.
Started publishing Jan 2020
Eric Topol’s newsletter is broader than obesity medicine, but it is still useful when GLP-1s, cardiometabolic health, and major shifts in medicine start to overlap. Read it for high-level context, strong interviews, and a physician-scientist view of where the category fits inside the bigger healthcare story. It is a good companion source when you want perspective, not just treatment chatter.
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.